ASHMI

**ASHMI** is a proprietary three-herb anti-asthma botanical drug candidate developed for the treatment of asthma, particularly allergic asthma. It was studied under a United States FDA Investigational New Drug framework and in clinical trials led by Icahn School of Medicine at Mount Sinai. Published clinical context describes ASHMI as an oral capsule formulation manufactured by Sino-Lion Pharmaceutical and designed as a Chinese herbal medicine intervention with immunomodulatory anti-asthma activity rather than a defined single-molecule target mechanism. In a phase I randomized placebo-controlled dose-escalation study in adults with allergic asthma, ASHMI appeared safe and well tolerated, which supported subsequent phase II evaluation for asthma efficacy.

Brand names

ASHMI

Other names

anti-asthma herbal medicine intervention